Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
ISPOR Barcelona 2018 posters

ISPOR Barcelona 2018 Posters

Contact Us
ISPOR Barcelona 2018 posters

Our 95 poster contributions at ISPOR demonstrate how we are putting science behind new and flexible study designs to address key research questions and specific therapy area challenges, enabling better healthcare decisions globally.

Check back on this page throughout the ISPOR Barcelona 2018 event as we'll be adding new posters after they've been presented.

Monday, November 12
  • DIFFERENTIAL PRICING FRAMEWORK TO EXPEDITE AND EXPAND ACCESS TO INNOVATIVE MEDICINE TO ALL PATIENTS  IN EUROPE
  • REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY
  • EVIDENCE-BASED VALUE OF PD-1/PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE
  • ONLINE METHODS TO ASSESS THE ELECTRONIC ADAPTATION OF THE TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION
  • PATIENT SATISFACTION WITH TREATMENT: CONCEPTUAL MODELS AND MEASURES
  • IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON- INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS): THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
  • IDENTIFICATION OF THE TREATMENT ATTRIBUTES TO BE CONSIDERED IN SHARED DECISION MAKING FOR ANKYLOSING SPONDYLITIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW
  • THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016
  • REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL: A PUBLIC HEALTHCARE DATABASE STUDY
  • SYMPTOM AND IMPACT DISTURBANCE: FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
  • CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES
Tuesday, November 13
  • LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
  • HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANY
  • COST COMPARISON: STRATEGIES OF PATIENTS MANAGEMENT IN ORAL ANTICOAGULANT THERAPY
  • PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS
  • TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
  • COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE
  • CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRE
Wednesday, November 14
  • TIME TO REIMBURSEMENT OF ONCOLOGY DRUGS IN BRAZIL: AN EXPLORATORY ANALYSIS FROM 2012 TO 2018
  • DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?: A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHES
  • CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY: AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD
Contact Us